|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
39 Trials |
|
5519 News |
|
| «12...1718192021222324252627...110111» |
- |||| metformin hydrochloride extended release / Generic mfg.
Trial primary completion date: Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Nov 17, 2016
P3, N=124, Recruiting, Sponsor: Dexa Medica Group
Trial primary completion date: Jan 2017 --> Jun 2017
- Trial completion, Enrollment change: Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains on Bacterial Vaginosis (clinicaltrials.gov) - Nov 17, 2016
P=N/A, N=36, Completed, Sponsor: Clinical Research Center Kiel GmbH
Trial primary completion date: Jan 2017 --> Jun 2017 Recruiting --> Completed | N=216 --> 36
- | Trial suspension, Trial primary completion date: Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis (clinicaltrials.gov) - Nov 17, 2016
P2, N=72, Suspended, Sponsor: GlaxoSmithKline
Recruiting --> Completed | N=216 --> 36 Recruiting --> Suspended | Trial primary completion date: Jul 2017 --> Dec 2016
- ||||||| progesterone / Generic mfg., dydrogesterone / Generic mfg.
Trial completion: Lotus It: A Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization (clinicaltrials.gov) - Nov 17, 2016
P3, N=1070, Completed, Sponsor: Abbott
Recruiting --> Suspended | Trial primary completion date: Jul 2017 --> Dec 2016 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion, Enrollment change: Bevacizumab and Carboplatin for Patients With Ovarian Cancer (clinicaltrials.gov) - Nov 16, 2016
P2, N=73, Completed, Sponsor: Vejle Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=30 --> 73
- | stenoparib (2X-121) / Allarity Therap, Oncoheroes
Trial completion, Combination therapy, Metastases: An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 16, 2016
P1/2, N=41, Completed, Sponsor: Eisai Limited
Active, not recruiting --> Completed | N=30 --> 73 Active, not recruiting --> Completed
- | veliparib (ABT-888) / AbbVie
Trial completion, Monotherapy, BRCA Biomarker, PARP Biomarker: Veli-BRCA: Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (clinicaltrials.gov) - Nov 16, 2016
P1/2, N=49, Completed, Sponsor: Vejle Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Menopur (menotropin) / Ferring
Enrollment open: A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur® (clinicaltrials.gov) - Nov 16, 2016
P=N/A, N=340, Recruiting, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV (clinicaltrials.gov) - Nov 15, 2016
P1/2, N=50, Recruiting, Sponsor: Izun Pharma Ltd
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Dec 2016
- ||| New trial, BRCA Biomarker: BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer (clinicaltrials.gov) - Nov 14, 2016
P=N/A, N=298, Completed, Sponsor: Samsung Medical Center
- Enrollment open: Quantitative MRI for Functional Imaging of the Testis: A New Methodology for Evaluation of the Infertile Male (clinicaltrials.gov) - Nov 14, 2016
P=N/A, N=20, Recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: Jun 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- Enrollment open, Trial initiation date: The Relationship Between Adipokines, Obesity and Insulin Resistance in Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Nov 10, 2016
P=N/A, N=75, Recruiting, Sponsor: Ain Shams University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Nov 2016
- Enrollment closed, Enrollment change: Hula, a Physical Activity Intervention for Female-Cancer Survivors (clinicaltrials.gov) - Nov 9, 2016
P=N/A, N=73, Active, not recruiting, Sponsor: University of Hawaii
Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Nov 2016 Recruiting --> Active, not recruiting | N=100 --> 73
- Trial completion: Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients (clinicaltrials.gov) - Nov 9, 2016
P=N/A, N=150, Completed, Sponsor: Fenway Community Health
Recruiting --> Active, not recruiting | N=100 --> 73 Recruiting --> Completed
- Trial completion: 3DRCT: Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? (clinicaltrials.gov) - Nov 8, 2016
P1, N=57, Completed, Sponsor: Brigham and Women's Hospital
Recruiting --> Completed Enrolling by invitation --> Completed
- New trial: Heart Rate Variability Biofeedback for Female Sexual Arousal Disorder (clinicaltrials.gov) - Nov 8, 2016
P=N/A, N=65, Recruiting, Sponsor: University of Texas at Austin
- | Phase classification, Preclinical: Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF) (clinicaltrials.gov) - Nov 7, 2016
P3b/4, N=172, Completed, Sponsor: Merck KGaA
Enrolling by invitation --> Completed Phase classification: P4 --> P3b/4
- || letrozole / Generic mfg.
Trial primary completion date: Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma (clinicaltrials.gov) - Nov 7, 2016
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P4 --> P3b/4 Trial primary completion date: Dec 2017 --> Dec 2018
- lidocaine topical / Generic mfg.
Trial completion: Efficacy of a Physiotherapy Treatment in Women Suffering From Provoked Vestibulodynia (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=212, Completed, Sponsor: Université de Sherbrooke
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Completed
- Trial primary completion date: Effect of Endometrial Scratching on Assisted Reproduction Outcomes: a Randomized Controlled Trial (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=600, Enrolling by invitation, Sponsor: University of Sao Paulo
Recruiting --> Completed Trial primary completion date: Sep 2016 --> Sep 2017
- Disalcid (salsalate) / Bausch Health
Enrollment change, Trial termination, Trial primary completion date: ELI-ROAS: Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=47, Terminated, Sponsor: Indiana University
N=60 --> 47 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Jun 2015; The PI left Indiana University. The findings served as preliminary data for a recently awarded NIH R01 grant.
- Trial primary completion date: Endometrial Scratching for Cryopreserved Embryo Transfer (clinicaltrials.gov) - Nov 4, 2016
P=N/A, N=300, Enrolling by invitation, Sponsor: University of Sao Paulo
The findings served as preliminary data for a recently awarded NIH R01 grant. Trial primary completion date: Jul 2016 --> Jul 2018
- Enrollment closed, Metastases: TIL Therapy for Metastatic Ovarian Cancer (clinicaltrials.gov) - Nov 4, 2016
P1, N=6, Active, not recruiting, Sponsor: Inge Marie Svane
Trial primary completion date: Jul 2016 --> Jul 2018 Recruiting --> Active, not recruiting
- || Enrollment closed, Trial primary completion date: M. D. Anderson Symptom Inventory - Ovarian Cancer (clinicaltrials.gov) - Nov 3, 2016
P=N/A, N=158, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Completed --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Mar 2017
- Enrollment closed, Enrollment change: What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography (clinicaltrials.gov) - Nov 3, 2016
P0, N=49, Active, not recruiting, Sponsor: University of Michigan
Completed --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Mar 2017 Recruiting --> Active, not recruiting | N=150 --> 49
- |||| anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Trial completion: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - Nov 3, 2016
P2b, N=305, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=150 --> 49 Active, not recruiting --> Completed
- carboplatin / Generic mfg., azacitidine / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Trial withdrawal: Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer (clinicaltrials.gov) - Nov 2, 2016
P1, N=0, Withdrawn, Sponsor: Loyola University
Active, not recruiting --> Completed N=18 --> 0 | Terminated --> Withdrawn
- Trial primary completion date: Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=25, Recruiting, Sponsor: University of Washington
N=18 --> 0 | Terminated --> Withdrawn Trial primary completion date: Aug 2014 --> Dec 2017
- carboplatin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment (clinicaltrials.gov) - Nov 1, 2016
P4, N=15, Terminated, Sponsor: Massachusetts General Hospital
Trial primary completion date: Aug 2014 --> Dec 2017 N=50 --> 15 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Mar 2015; Extended Carboplatin Infusion did not Reduce Frequency of Hypersensitivity Reactions
- Trial completion: Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=33, Completed, Sponsor: Royal Marsden NHS Foundation Trust
N=50 --> 15 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Mar 2015; Extended Carboplatin Infusion did not Reduce Frequency of Hypersensitivity Reactions Recruiting --> Completed
- Trial completion, Trial primary completion date, Adverse events: Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=177, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Dec 2012
- || Kombiglyze XR (saxagliptin/metformin XR) / AstraZeneca
Trial completion, Monotherapy: BMS-AZPCOS: Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis (clinicaltrials.gov) - Nov 1, 2016
P3, N=38, Completed, Sponsor: Woman's
Recruiting --> Completed | Trial primary completion date: Apr 2012 --> Dec 2012 Active, not recruiting --> Completed
- New trial, Metastases: Clinical Trial of Laparoscopic Pelvic and Para-aortic Lymphadenectomy and Uterine Blood Vessel Blocking for Precision Diagnosis and Treatment in Advanced Cervical Cancer (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=50, Not yet recruiting, Sponsor: Shanghai First Maternity and Infant Hospital
- Enrollment open: LO2: Evaluation of the Impact of Reduced Oxygen Concentration on Embryonic Development (clinicaltrials.gov) - Oct 29, 2016
P=N/A, N=60, Recruiting, Sponsor: Reproductive Medicine Associates of New Jersey
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | New P2 trial, Surgery: Surgicel Reduces Ovarian Endometriomas Recurrence (clinicaltrials.gov) - Oct 28, 2016
P2, N=200, Recruiting, Sponsor: Cairo University
- cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (clinicaltrials.gov) - Oct 28, 2016
P1, N=27, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Not yet recruiting --> Recruiting N=60 --> 27
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial completion, Enrollment change: Letrozole Versus Clomifene Citrate for Ovulation Induction (clinicaltrials.gov) - Oct 28, 2016
P4, N=159, Completed, Sponsor: University of Nottingham
N=60 --> 27 Recruiting --> Completed | N=212 --> 159
- nintedanib / Generic mfg.
Trial completion: Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Oct 28, 2016
P2, N=36, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed | N=212 --> 159 Active, not recruiting --> Completed
- Trial completion: Collecting Tumor Samples From Patients With Gynecological Tumors (clinicaltrials.gov) - Oct 28, 2016
P=N/A, N=275, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Recruiting --> Completed
- Trial primary completion date: Understanding the Value of Community Vital Signs in Primary Care (clinicaltrials.gov) - Oct 28, 2016
P=N/A, N=170000, Recruiting, Sponsor: Virginia Commonwealth University
Recruiting --> Completed Trial primary completion date: Aug 2016 --> Mar 2017
- | quisinostat (JNJ 26481585) / ChemRar, Viriom
New P2 trial, Combination therapy, BRCA Biomarker, Epigenetic controller, Metastases: Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy (clinicaltrials.gov) - Oct 27, 2016
P2, N=30, Recruiting, Sponsor: NewVac LLC
- | PD 360324 / Pfizer
New P2 trial: PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Oct 27, 2016
P2, N=15, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Trial completion, Enrollment change, Trial primary completion date: BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study (clinicaltrials.gov) - Oct 27, 2016
P2/3, N=13, Completed, Sponsor: University of British Columbia
Trial primary completion date: Aug 2016 --> Mar 2017 Recruiting --> Completed | N=240 --> 13 | Trial primary completion date: Dec 2016 --> Nov 2015
- Utrogestan (progesterone) / Besins Healthcare
Preclinical, Trial primary completion date: Implantation Enhancement by Elective Cryopreservation of All Viable Embryos (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=212, Recruiting, Sponsor: Universitair Ziekenhuis Brussel
Recruiting --> Completed | N=240 --> 13 | Trial primary completion date: Dec 2016 --> Nov 2015 Trial primary completion date: Sep 2016 --> Dec 2016
- New trial: Advancing HIV Prevention and Linkage to Care Among MSM With Gamification (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=120, Recruiting, Sponsor: University of California, Berkeley
- progesterone / Generic mfg.
Enrollment change, Trial withdrawal: Progesterone for First Trimester Vaginal Bleeding (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=0, Withdrawn, Sponsor: Soroka University Medical Center
Trial primary completion date: Sep 2016 --> Dec 2016 N=200 --> 0 | Not yet recruiting --> Withdrawn
- progesterone / Generic mfg., estradiol valerate / Generic mfg., triptorelin / Generic mfg.
Trial completion: ERAMAD: Endometrial Receptivity After GnRH Agonist Triggering (clinicaltrials.gov) - Oct 27, 2016
P4, N=35, Completed, Sponsor: IVI Madrid
N=200 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed
- Trial primary completion date: Homeopathic Treatment of Chronic Pelvic Pain in Women With Endometriosis (clinicaltrials.gov) - Oct 26, 2016
P4, N=50, Active, not recruiting, Sponsor: University of Sao Paulo General Hospital
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Oct 2016
- Enrollment closed: Zambia One Love Aim 3 Trial (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=3450, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2015 --> Oct 2016 Recruiting --> Active, not recruiting
- indomethacin / Generic mfg.
Trial primary completion date, Combination therapy: PIFA: Phase I Platinum Based Chemotherapy Plus Indomethacin (clinicaltrials.gov) - Oct 26, 2016
P1, N=18, Recruiting, Sponsor: UMC Utrecht
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2016 --> Dec 2018